Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Other Working Capital Changes: 2019-2025

Historic Other Working Capital Changes for IDEAYA Biosciences (IDYA) over the last 7 years, with Sep 2025 value amounting to -$192,000.

  • IDEAYA Biosciences' Other Working Capital Changes fell 120.15% to -$192,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year increase of 33.69%. This contributed to the annual value of $6.2 million for FY2024, which is 144.89% up from last year.
  • According to the latest figures from Q3 2025, IDEAYA Biosciences' Other Working Capital Changes is -$192,000, which was down 138.40% from $500,000 recorded in Q2 2025.
  • In the past 5 years, IDEAYA Biosciences' Other Working Capital Changes registered a high of $3.1 million during Q1 2024, and its lowest value of -$26.3 million during Q3 2022.
  • Over the past 3 years, IDEAYA Biosciences' median Other Working Capital Changes value was $357,000 (recorded in 2024), while the average stood at -$481,909.
  • Per our database at Business Quant, IDEAYA Biosciences' Other Working Capital Changes tumbled by 482.06% in 2021 and then soared by 220.50% in 2024.
  • Quarterly analysis of 5 years shows IDEAYA Biosciences' Other Working Capital Changes stood at -$2.0 million in 2021, then slumped by 96.21% to -$3.8 million in 2022, then surged by 62.41% to -$1.4 million in 2023, then spiked by 220.50% to $1.7 million in 2024, then plummeted by 120.15% to -$192,000 in 2025.
  • Its last three reported values are -$192,000 in Q3 2025, $500,000 for Q2 2025, and $2.0 million during Q1 2025.